JW secures biweekly obesity drug, eyes fast commercialization
JW Pharmaceutical has entered the fast-growing obesity treatment market by securing rights to a biweekly injectable drug candidate, betting on improved convenience as a competitive edge.The company announced that it signed an exclusive licensing agreement with Gan & Lee Pharmaceuticals on April 8 for the GLP-1 receptor agonist candidate Bofanglutide, gai..